4312-44-1

Usage

Uses

Used in Pharmaceutical Industry:
6-Hydroxy-4-quinolinecarboxylic acid is used as an active pharmaceutical ingredient for its demonstrated antibacterial and antiviral properties, making it a valuable compound in the development of new medications to combat infectious diseases.
Used in Chelating Agents:
In the chemical industry, 6-Hydroxy-4-quinolinecarboxylic acid is used as a chelating agent for metal ions, which is crucial in various applications such as environmental remediation and the stabilization of metal-containing compounds.
Used in Synthesis of Drug Molecules:
6-Hydroxy-4-quinolinecarboxylic acid is utilized as a building block in the synthesis of a variety of drug molecules, contributing to the creation of novel therapeutic agents with diverse mechanisms of action.
Used in Development of Fluorescent Probes:
In the field of biological research, 6-Hydroxy-4-quinolinecarboxylic acid is used in the development of fluorescent probes for detecting and monitoring metal ions in biological systems, aiding in the study of metal ion homeostasis and its role in various physiological and pathological processes.

Upstream product

• 86-68-0 6-methoxyquinoline-4-carboxylic acid 

Downstream Products

• 580-16-5 6-hydroxyquinoline 
• 859780-30-6 6-hydroxy-quinoline-4-carbonyl chloride 
• 31610-09-0 Xanthochininsaeure-ethylester 
• 525-39-3 6-ethoxy-quinoline-4-carboxylic acid 

Relevant academic research and scientific papers

FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS

The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the prese

MARKING PRECURSOR WITH SQUARIC ACID COUPLING

The invention relates to a marking precursor incorporating a chelator or fluorination group for radiolabelling with 44Sc, 47Sc, 55Co, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 89Zr, 86Y, 90Y, 90Nb, 99mTc, 111ln, 135Sm, 140Pr, 159Gd, 149Tb, 160Tb, 161Tb, 165Er, 166Dy, 166Ho, 175Yb, 177Lu, 186Re, 188Re, 213Bi and 225Ac or with 18F, 131I or 211At, and one or two biological targeting vectors which are coupled to the chelator or fluorinating group via one or more squaric acid groups.

SPECT imaging agent for FAP-alpha specific tumor diagnosis

The invention relates to an SPECT imaging agent for FAP-alpha specific tumor diagnosis. The imaging agent is formed by taking a micromolecular FAP-alpha inhibitor of a modified N-4-quinolyl-glycine-(2S)-cyanoproline skeleton as a precursor compound, taking 99mTc as radionuclide and taking N-tris (hydroxymethyl) methylglycine (Tricine) and triphenylphosphine tri-m-sodium sulfonate (TPPTS) as synergistic ligands. Compared with the prior art, the imaging agent has high sensitivity, more excellent in-vivo biological distribution is shown, compared with the prior art, the complex has the advantagesof higher tumor uptake and tumor/organ uptake ratio, more stable coordination property, and excellent in-vivo and in-vitro stability. Due to the obvious coordination structure characteristics of theimaging agent, a one-step marking kit technology can be used, and the imaging agent has better druggability and is suitable for industrial production and clinical popularization.

FAP INHIBITOR

The present invention relates to a compound, a liposome comprising said compound, a virus-like particle comprising said compound, a pharmaceutical composition comprising or consisting of said compound, said liposome or said virus-like particle, a kit comprising or consisting of said compound, said liposome, said virus-like particle or said pharmaceutical composition and use of the compound, liposome, virus-like particle or pharmaceutical composition in the treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).